Effectiveness of early exercise on reducing skeletal muscle loss during preoperative neoadjuvant chemotherapy for esophageal cancer

Surgery Today ◽  
2022 ◽  
Author(s):  
Tomohiro Ikeda ◽  
Kazuhiro Noma ◽  
Naoaki Maeda ◽  
Shunsuke Tanabe ◽  
Yoko Sakamoto ◽  
...  
2021 ◽  
Vol 34 (Supplement_1) ◽  
Author(s):  
Kazuya Higashizono ◽  
Shinsuke Sato ◽  
Erina Nagai ◽  
Yusuke Taki ◽  
Masato Nishida ◽  
...  

Abstract   It is known that various factors, including surgical stress, nutritional deficits and sarcopenia, affect the incidence of postoperative complications. The aim of this study is to identify the predictors of major complications (Clavien-Dindo ≥II) after esophageal resection following neoadjuvant chemotherapy (NAC). Methods Forty-nine patients with esophageal cancer undergoing NAC and surgery between January 2017 and December 2019 were identified from our surgery database and retrospectively analyzed. Onodera prognostic nutritional index (PNI) was used as the indicator of nutritional status. For the evaluation of skeletal muscle mass, computed tomography imaging of the total cross-sectional muscle tissue measured at the third lumbar level defined the skeletal muscle index (SMI). Images were collected before and after NAC. Univariate and multivariate logistic regression analyses were used to assess the association between various predictors and major postoperative complications. Results Of the Forty-nine patients, 20 patients (40.8%) had major complication after surgery. Of the 20 patients, 5 had pneumonia and 4 had anastomotic leakage. Nine patients (18.3%) complete planned dose of NAC. SMI reduction was observed in 42 patients (85.7%) during NAC. According to univariate analysis, SMI reduction during NAC, and PNI before chemotherapy were significantly associated with major postoperative complications (P = 0.032, P = 0.035, respectively). According to multivariate analysis, SMI reduction during NAC is an independent predictor for the incidence of major postoperative complications (P = 0.0034). Conclusion Skeletal muscle loss during neoadjuvant chemotherapy can be an useful predictor of major postoperative complications in patients with esophageal cancer.


Surgery Today ◽  
2019 ◽  
Vol 49 (12) ◽  
pp. 1022-1028 ◽  
Author(s):  
Naoki Kamitani ◽  
Kazuhiro Migita ◽  
Sohei Matsumoto ◽  
Kohei Wakatsuki ◽  
Tomohiro Kunishige ◽  
...  

Author(s):  
Kazuaki Matsui ◽  
Hirofumi Kawakubo ◽  
Shuhei Mayanagi ◽  
Satoru Matsuda ◽  
Tomoyuki Irino ◽  
...  

Summary Sarcopenia, which involves two important aspects, namely skeletal muscle loss and decreased physical function, was suggested as a poor prognostic factor in esophageal cancer surgery. The purpose of this study was to clarify the perioperative change in daily physical activity and propose effective preventive strategies. We prospectively enrolled patients with esophageal cancer who were scheduled to undergo radical esophagectomy. Their daily physical activities were recorded using an accelerometer before surgery, immediately after discharge, and 6 months after surgery. The relationships of physical activity level and the perioperative factors, especially skeletal muscle change, with the risk factors of low daily activity level were investigated. The data of 20/28 enrolled patients were analyzed. The mean activity level of the 20 patients decreased after discharge and subsequently recovered on postoperative month 6. The percentage of activity levels >1.5 metabolic equivalents/day after discharge significantly correlated to the change rate in total muscle cross-sectional area from baseline to POM 6 (r = 0.452, P = 0.045). In a stepwise multiple regression analysis, age, neoadjuvant chemotherapy, and anastomotic leakage were identified as negative associated factors of activity time at >1.5 metabolic equivalents at postoperative month 6. Activity level immediately after discharge was significantly associated with skeletal muscle loss at postoperative month 6 in patients with esophageal cancer who underwent esophagectomy. Elderly patients and patients who received neoadjuvant chemotherapy and had an anastomotic leakage might require intensive prevention. Prospective interventions aimed at increasing daily activity can prevent sarcopenia.


2020 ◽  
Vol 18 (1) ◽  
Author(s):  
Naoaki Maeda ◽  
Yasuhiro Shirakawa ◽  
Shunsuke Tanabe ◽  
Kazufumi Sakurama ◽  
Kazuhiro Noma ◽  
...  

2019 ◽  
Vol 26 (11) ◽  
pp. 3727-3735 ◽  
Author(s):  
Keita Takahashi ◽  
Masayuki Watanabe ◽  
Ryotaro Kozuki ◽  
Tasuku Toihata ◽  
Akihiko Okamura ◽  
...  

2019 ◽  
Vol 27 (2) ◽  
pp. 492-498 ◽  
Author(s):  
Yuichiro Nakashima ◽  
Hiroshi Saeki ◽  
Qingjiang Hu ◽  
Yasuo Tsuda ◽  
Yoko Zaitsu ◽  
...  

Cancers ◽  
2021 ◽  
Vol 13 (8) ◽  
pp. 1806
Author(s):  
Byung Min Lee ◽  
Yeona Cho ◽  
Jun Won Kim ◽  
Sung Gwe Ahn ◽  
Jee Hung Kim ◽  
...  

There are no means to predict patient response to neoadjuvant chemotherapy (NAC); the impact of skeletal muscle loss on the response to NAC remains undefined. We investigated the association between response to chemotherapy and skeletal muscle loss in breast cancer patients. Patients diagnosed with invasive breast cancer who were treated with NAC, surgery, and radiotherapy were analyzed. We quantified skeletal muscle loss using pre-NAC and post-NAC computed tomography scans. The response to treatment was determined using the Response Evaluation Criteria in Solid Tumors. We included 246 patients in this study (median follow-up, 28.85 months). The median age was 48 years old (interquartile range 42–54) and 115 patients were less than 48 years old (46.7%). Patients showing a complete or partial response were categorized into the responder group (208 patients); the rest were categorized into the non-responder group (38 patients). The skeletal muscle mass cut-off value was determined using a receiver operating characteristic curve; it showed areas under the curve of 0.732 and 0.885 for the pre-NAC and post-NAC skeletal muscle index (p < 0.001 for both), respectively. Skeletal muscle loss and cancer stage were significantly associated with poor response to NAC in locally advanced breast cancer patients. Accurately measuring muscle loss to guide treatment and delaying muscle loss through various interventions would help enhance the response to NAC and improve clinical outcomes.


2021 ◽  
Author(s):  
Masatsugu Amitani ◽  
Takaaki Oba ◽  
Hiroki Morikawa ◽  
Tatsunori Chino ◽  
Ai Soma ◽  
...  

Abstract Background: The skeletal muscle index (SMI), which is calculated as the ratio of skeletal muscle area at the third lumbar vertebral level divided by height squared, has been considered a prognostic factor in patients with breast cancer. However, the prognostic impact of changes in SMI during treatment remains unclear. This study aimed to evaluate the influence of SMI changes in patients with breast cancer undergoing neoadjuvant chemotherapy (NAC).Methods: We reviewed patients with breast cancer who underwent NAC and subsequent surgery for breast cancer between 2010 and 2017. The rate of SMI change during NAC was calculated, and the association between SMI changes and prognosis was retrospectively analyzed.Results: In total, 144 patients were evaluated. 48 (33.3%), 56 (38.9%), and 40 (27.8%) patients exhibited increased (≥ 3%), maintained (−3% <, < 3%), and decreased (−3% ≥) SMI during NAC, respectively. The decreased SMI group showed significantly poorer disease-free survival than the maintained and increased SMI groups (hazard ratio [HR] 8.82, p < 0.001 for the decreased vs. increased SMI groups; HR 3.72, p < 0.001 for the decreased vs. maintained SMI groups). Moreover, decreased SMI was an independent risk factor for disease-free survival in multivariate analysis (HR 4.20, p < 0.01).Conclusions: Skeletal muscle loss during NAC predicts poor prognosis. Our results underscore the importance of monitoring and maintaining skeletal muscle mass during NAC.


Sign in / Sign up

Export Citation Format

Share Document